Repligen Corp (RGEN): Howard Benjamin , other of Repligen Corp sold 2,889 shares on May 11, 2016. The Insider selling transaction was reported by the company on May 13, 2016 to the Securities and Exchange Commission. The shares were sold at $26.72 per share for a total value of $77,199.28 , the company said in a SEC Form 4 Filing.
Other Insider transactions have been reported by the company according to SEC Form 4, on Jun 10, 2015, Howard Benjamin (other) sold 35,000 shares at $37.90 per share price.On May 19, 2015, James R Rusche (Senior Vice President) sold 15,000 shares at $41.32 per share price.Also, On May 14, 2015, Walter C Herlihy (PRESIDENT, CEO) sold 45,431 shares at $38.97 per share price.On May 12, 2015, Thomas F Jr Ryan (director) sold 20,000 shares at $37.19 per share price.
Shares of Repligen Corporation (RGEN) ended Tuesday, May 10, 2016 session in red amid volatile trading. The shares closed down -0.09 points or -0.33% at $26.86 with 2,34,924 shares getting traded. Post opening the session at $27.2, the shares hit an intraday low of $26.29 and an intraday high of $27.38 and the price vacillated in this range throughout the day. The company has a market cap of $904 M and the number of outstanding shares has been calculated to be 3,36,38,643 shares. The 52-week high of Repligen Corporation is $42.48 and the 52-week low is $20.07.
Company has been under the radar of several Street Analysts.Repligen Corporation is Initiated by Craig Hallum to Buy. The Rating was issued on Feb 22, 2016.
Repligen Corporation (Repligen) is a life sciences company. The Company develops manufactures and markets bioprocessing products for life sciences and biopharmaceutical companies across the world. The Company is a manufacturer of both native and recombinant forms of Protein A critical reagents used in biomanufacturing to purify monoclonal antibodies which is a type of biologic drug. It also supplies several growth factor products and cell filtration products used to increase cell culture productivity during the bioproduction process. It has developed a series of OPUS chromatography columns for use in clinical-scale manufacturing. It manufactures and sells Protein A and growth factors to life sciences companies under supply agreements and sells chromatography columns as well as media and quality test kits and the Company’s Alternating Tangential Flow (ATF) products directly to biopharmaceutical companies or contract manufacturing organizations or through distributors.